# Zikani Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zikani-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Watertown, US
- Website: www.zikani.com
- Total disclosed funding: $20M
- Latest round: Series A (Apr 20, 2020)
- Investors on record: 5

## About

Founded in 2014 and based in Massachusetts, US, Zikani Therapeutics, Inc., formerly known as Macrolide Pharmaceuticals, Inc., is a preclinical-stage company that focuses on developing novel antibiotic compounds to relieve patient suffering from serious infections and rare diseases.

## Funding rounds

- Series A, Apr 20, 2020, $7.5M — Roche Venture Fund, Gurnet Point Capital, Advent Life Sciences
- Series A, Apr 29, 2016, $4M — Novartis Venture Fund, SR One, Roche Venture Fund, Gurnet Point Capital, Advent Life Sciences
- Series A, Feb 10, 2015, $8.2M — Novartis Venture Fund, SR One, Roche Venture Fund, Gurnet Point Capital

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A
- Gurnet Point Capital (https://capitalatlas.ai/funds/gurnet-point-capital) — Series A
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A